DOAC - Dosing Options in AntiCoagulation Prophylaxis
A legfontosabb adatok
- Ki végzi
- University of Vermont
- Hol
- Burlington (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 996 fő, tervezett
- Kezdés
- 2025. okt. 17.
- Várható befejezés
- 2035. aug.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Apixaban 2.5 mg twice daily
- Apixaban 5 mg once daily
- No anticoagulation
- A regiszteradat frissítve
- 2026. február 5.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with an active solid tumor or lymphoma who are starting or changing cancer treatment and have a medium risk of blood clots.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Active solid tumor or lymphoma. Khorana Risk Score of 2, a medium risk of blood clots.
- Korábbi kezelés
- Must be starting a new cancer treatment that works through the whole body, or changing cancer treatment. Cannot be on full-dose blood thinners now.
- Biomarker vagy leletérték
- Khorana Risk Score of 2, worked out from lab and clinical data when treatment starts.
A részvétel fő kizáró okai
- Active bleeding or high risk of bleeding, such as recent major surgery or brain tumors that may bleed
- Cannot take apixaban, for example allergy, severe liver disease or certain other drugs
- Platelet count < 50,000/µL or creatinine clearance < 25 mL/min
- Life expectancy < 3 months
- Pregnant or breastfeeding
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Diagnosed with an active solid tumor or lymphoma
- Starting a new systemic cancer treatment or changing cancer treatment
- Khorana Risk Score of 2 (calculated based on lab and clinical data at treatment initiation)
- Not currently receiving therapeutic anticoagulation
- Able to provide informed consent
Ki nem vehet részt
- Active bleeding or high risk of bleeding (e.g., recent major surgery, CNS tumors with hemorrhagic risk)
- Known contraindication to apixaban (e.g., allergy, severe liver disease, dual strong CYP3A4 and P-gp inhibitors)
- Platelet count < 50,000/µL
- Creatinine clearance < 25 mL/min
- Current therapeutic-dose anticoagulation for VTE or atrial fibrillation
- Life expectancy < 3 months
- Pregnant or breastfeeding
- Inability to comply with study procedures
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- University of Vermont Medical CenterBurlington, Egyesült ÁllamokContact: Steven Ades, MD, MScRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience.
A teljes eredeti leírásKevesebb
This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of blood clots and death in cancer patients who are at moderate risk for VTE. The study focuses on people who have a "Khorana score" of 2, which puts them at intermediate risk for developing blood clots.
The study will include approximately 996 participants with solid tumors or lymphoma who are starting or recently started cancer-directed therapy. Participants will be randomly assigned to one of three groups:
Group 1: Apixaban 2.5 mg twice a day (standard prophylactic dose)
Group 2: Apixaban 5 mg once a day (an alternative, more convenient dose)
Group 3: No anticoagulant (standard care)
Participants will take the assigned treatment (if applicable) for 6 months. Researchers will monitor whether participants develop blood clots, experience serious bleeding events, or die from any cause during the study period.
By comparing these three groups, the researchers hope to learn whether a once-daily dose of apixaban can work as well as the standard twice-daily dose, and whether either dosing strategy is better than no anticoagulation at all. If successful, the study may help increase the safe use of VTE prevention in cancer patients and improve overall outcomes, especially in patients at intermediate risk.
This is a pragmatic trial, meaning it is designed to fit into real-world clinical practice with minimal extra procedures. The study drug is not provided by the sponsor and will be prescribed and filled through usual care channels. Participants and their doctors will decide whether to continue the medication after the study ends.
A vizsgálat 3 csoportja
- Arm 1: Apixaban 2.5 mg Twice Daily ProphylaxisA vizsgált kezelés
Participants in this arm will receive apixaban 2.5 mg by mouth twice daily (BID) for 6 months. This is the guideline-supported prophylactic dose for VTE prevention in high-risk ambulatory cancer patients.
Kezelés: Apixaban 2.5 mg twice daily
- Arm 2 Title: Apixaban 5 mg Once Daily ProphylaxisA vizsgált kezelés
Participants in this arm will receive apixaban 5 mg by mouth once daily for 6 months. This alternative dosing schedule is being tested for its potential to improve adherence and maintain VTE protection in moderately high-risk cancer outpatients.
Kezelés: Apixaban 5 mg once daily
- No Anticoagulation (Control)Már használt kezelés, összehasonlításként
Participants in this arm will not receive any anticoagulant prophylaxis. This approach reflects current standard-of-care practice for many patients with a Khorana Risk Score of 2, where anticoagulation is not routinely prescribed.
Kezelés: No anticoagulation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Comparison of Anticoagulant Dosing Strategies to Reduce VTE and Mortality in Cancer Outpatients: A Randomized, Pragmatic Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. február 5.